Kymera Therapeutics Inc

NASDAQ:KYMR   3:59:53 PM EDT
21.62
+0.67 (+3.20%)
Products

Kymera Therapeutics Receives FDA Orphan Drug Designation For KT-333

Published: 09/15/2022 11:47 GMT
Kymera Therapeutics Inc (KYMR) - Kymera Therapeutics Receives FDA Orphan Drug Designation for Kt-333, a First-in-class, Investigational Stat3 Degrader for the Treatment of Cutaneous T-cell Lymphoma.